Nektar Therapeutics (NKTR) Enterprise Value (2010 - 2026)

Nektar Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$568.6 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 160.07% year-over-year to -$568.6 million in Q1 2026; TTM through Mar 2026 was -$568.6 million, a 160.07% decrease from a year earlier, with the FY2025 full-year figure at -$245.8 million, up 3.71% from the prior year.
• Enterprise Value slipped to -$568.6 million in Q1 2026 per NKTR's latest filing, from -$245.8 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$175.9 million in Q2 2025 and bottomed at -$667.0 million in Q1 2022.
• The 5-year median for Enterprise Value is -$303.6 million (2023), against an average of -$377.6 million.
• Across the five-year window, Enterprise Value jumped 40.68% in 2022 and tumbled 160.07% in 2026, its largest moves.
• Year by year, Enterprise Value stood at -$505.0 million in 2022, then surged by 39.88% to -$303.6 million in 2023, then grew by 15.94% to -$255.2 million in 2024, then rose by 3.71% to -$245.8 million in 2025, then slumped by 131.37% to -$568.6 million in 2026.
• Per Business Quant, the three latest NKTR Enterprise Value figures stand at -$568.6 million (Q1 2026), -$245.8 million (Q4 2025), and -$270.2 million (Q3 2025).